Oligonucléotides antisens en chimiothérapie antivirale : problèmes et perspectives d'utilisation

Agrawal, 1996, Antisense oligonucleotides: towards clinical trials, Trends Biotechnol., 14, 376, 10.1016/0167-7799(96)10053-6 Bock, 1992, Selection of single-stranded DNA molecules that bind and inhibit human thrombin, Nature, 355, 564, 10.1038/355564a0 Branch, 1998, A good antisense molecule is hard to find, Trends Biochem. Sci., 23, 45, 10.1016/S0968-0004(97)01155-9 Cook, 1993, Medicinal chemistry strategies for antisense research, 149 Couture, 1996, Anti-gene therapy: the use of ribozymes to inhibit gene function, Trends Genet, 12, 510, 10.1016/S0168-9525(97)81398-4 Crooke, 1996, Progress in antisense oligonucleotide therapeutics, Annu. Rev. Pharmacol. Toxicol., 36, 107, 10.1146/annurev.pa.36.040196.000543 Crooke, 1997, Progress in antisense therapeutics discovery and development, 158 Fearon, 1997, Phosphorothioate oligdeoxynucleotides: large-scale synthesis and analysis, impurity characterization, and the effects of phosphorus stereochemistry, 19 Giovannangeli, 1997, Progress in developments of triplex-based strategies, Antisense Nucleic Acid Drug Dev., 7, 413, 10.1089/oli.1.1997.7.413 Gregoriadis, 1996, Targeting of drugs, 5: Strategies for oligonucleotide and gene delivery in therapy, 206 Ho, 1998, Mapping of RNA accessible sites for antisense experiments with oligonucleotide libraries, Nat. Biotechnol., 16, 59, 10.1038/nbt0198-59 Kandimalla, 1997, Mixed backbone antisense oligonucleotides: design, biochemical and biological properties of oligonucleotides containing 2′-5′-ribo- and 3′- 5′-deoxyribonucleotide segments, Nucleic Acids Res., 25, 370, 10.1093/nar/25.2.370 Kulka, 1989, Site specificity of the inhibitory effects of oligo(nucleoside methylphosphonate)s complementary to the acceptor splice junction of herpes simplex virus type 1 immediate early mRNA 4, 86, 6868 Larrouy, 1995, RNase H is responsible for the non-specific inhibition of in vitro translation by 2′-O-alkyl chimeric oligonucleotides: high affinity or selectivity, a dilemma to design antisense oligomers, Nucleic Acids Res., 23, 3434, 10.1093/nar/23.17.3434 Lima, 1997, Combinatorial screening and rational optimization for hybridization to folded hepatitis C virus RNA of oligonucleotides with biological antisense activity, J. Biol. Chem., 272, 626, 10.1074/jbc.272.1.626 Matteucci, 1997, Oligonucleotide analogues: an overview, 15 Mirabelli, 1993, Antisense oligonucleotides in the context of modern molecular drug discovery and development, 7 Monia, 1996, Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase, Nat. Med., 2, 668, 10.1038/nm0696-668 Southern, 1997, Discovering antisense reagents by hybridization of RNA to oligonucleotide arrays, 38 Stein, 1994, Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides, Antisense Res. Dev., 4, 67, 10.1089/ard.1994.4.67 Stephenson, 1978, Inhibition of Rous sarcoma viral RNA translation by a specific oligodeoxyribonucleotide, 75, 285 Sullenger, 1990, Overexpression of TAR sequences renders cells resistant to human immunodeficiency virus replication, Cell., 63, 601, 10.1016/0092-8674(90)90455-N Sullenger, 1991, Analysis of trans-acting response decoy RNA-mediated inhibition of human immunodeficiency virus type 1 transactivation, J. Virol., 65, 6811, 10.1128/JVI.65.12.6811-6816.1991 Toulme, 1997, Rational and combinatorial strategies for designing oligonucleotides targeted to RNA structures, 36, 39 Toulme, 1998, Les aptamères : des ligands et des catalyseurs oligonucléotidiques obtenus par sélection in vitro, Médecine sciences, 14, 155, 10.4267/10608/1003 Wagner, 1997, Antisense technology and prospects for therapy of viral infections and cancer, Mol. Med. Today, 3, 31, 10.1016/S1357-4310(96)10053-8 Zamecnik, 1978, Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide, 75, 280